Stocks · News reference

Smith & Nephew Lowers FY2026 Sales Guidance from $6B to $6B vs $1.602B Est

Aug 4, 2026, 10:15 AMBenzinga Newsdesk

Smith & Nephew (NYSE:SNN) lowers FY2026 sales outlook from $6Billion to $6Billion vs $1.602 billion estimate.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 4, 2026, 10:15 AM
Checked: Aug 4, 2026, 10:15 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 8, 2026, 4:05 PMBenzinga News-desk
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it was likely to miss its FY26 and Q3 adjusted EPS and net sales growth guidance following a previously announced cybersecurity incident that affected operations.
ABT BAX BDX DXCM GMED
BenzingaSep 8, 2026, 11:33 AMAvi Kapoor
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Analyst ratings and news for high-yield healthcare stocks Medtronic (3.06%), Smith & Nephew (2.74%) and GSK (3.65%).
GSK MDT SNN
BenzingaAug 31, 2026, 11:46 AMAvi Kapoor
This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Evercore ISI
ATTO BRVE LITE SNN TP
BenzingaAug 31, 2026, 9:37 AMBenzinga Newsdesk
BTIG Initiates Coverage On Smith & Nephew with Neutral Rating
SNN